# Sunitinib to Treat Recurrent Brain Cancer

> **NCT00923117** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 87 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Malignant Gliomas
- Anaplastic Gliomas

## Interventions

- **DRUG:** Sutent (sunitinib)

## Key facts

- **NCT ID:** NCT00923117
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 87 (ACTUAL)
- **Why stopped:** The study was terminated based on results of an interim analysis for futility.
- **Last updated:** 2015-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00923117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00923117, "Sunitinib to Treat Recurrent Brain Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00923117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*